PAH News

Bayer’s Adempas (riociguat) can improve the lung and heart functioning of pulmonary hypertension patients who fail to respond to phosphodiesterase-5 inhibitors (PDE5i), a Phase 3 clinical trial suggests. The RESPITE trial ... Read more

September 15, 2017September 15, 2017

Study Examines Risk Factors Between Pulmonary Arterial Hypertension and SLE

News, PAH News

Pulmonary arterial hypertension (PAH) is a rare complication of systemic lupus erythematosus (SLE) and is associated with the presence of specific autoantibodies, a study has found. PAH is a complex ... Read more

September 12, 2017September 12, 2017

Uptravi Improves Connective Tissue Disease-Associated PAH, Regardless of Disease Subtype, Trial Shows

News, PAH News

Uptravi (selexipag) slows the progression of connective tissue disease associated with pulmonary arterial hypertension, regardless of the type of connective tissue disease, according to a Phase 3 clinical trial in ... Read more

September 11, 2017September 11, 2017

Pulmonary Hypertension Survival Rates Vary with Cause of Disease, German Study Finds

News, PAH News, PH News

Information from a pulmonary hypertension registry at Germany’s University Hospital Giessen indicates that patient survival rates vary with the cause of their disease. Researchers published the results in The Journal of Heart and ... Read more

September 7, 2017September 7, 2017

Tracleer Becomes First FDA-approved Therapy in U.S. for Children with Pulmonary Hypertension

News, PAH News

Tracleer (bosentan) has become the first therapy to obtain U.S. regulatory approval for treating pulmonary hypertension in children. The Food and Drug Administration authorized it for children aged 3 and older who ... Read more

September 5, 2017September 5, 2017

FDA Declines SteadyMed’s New Drug Application for Trevyent, Delivered via PatchPump, to Treat PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has declined SteadyMed Therapeutics‘ new drug application (NDA) for its Trevyent (treprostinil injection) therapy to treat pulmonary arterial hypertension (PAH). SteadyMed, with offices in San Ramon, California, ... Read more

September 1, 2017September 1, 2017

Reata Recruiting More Pulmonary Hypertension Patients to Its Bardoxolone Methyl Trials

News, PAH News, PH News

Three ongoing clinical trials are recruiting additional participants to allow for more robust assessments of Reata Pharmaceuticals’ bardoxolone methyl therapy as a potential treatment for various forms of pulmonary hypertension. ... Read more

August 29, 2017September 6, 2017

Uptravi Slows Progression of Pulmonary Hypertension Stemming from Connective Tissue Disease, Study Finds

News, PAH News

Actelion’s Uptravi (selexipag) delays the progression of pulmonary arterial hypertension that stems from connective tissue disease, a follow-up analysis of Phase 3 clinical trial findings indicates. People with PAH-CTD also ... Read more

August 25, 2017August 25, 2017

Arena to Present New Information on Its Pulmonary Hypertension Therapy Ralinepag in Barcelona

News, PAH News

Arena Pharmaceuticals will present new information in Barcelona this weekend on its pulmonary hypertension therapy ralinepag, which a clinical trial showed improved patients’ heart blood vessel resistance and exercise capacity. The ... Read more

August 23, 2017August 23, 2017

VMS Heart Analysis System Accurately Evaluates Right Ventricle Remodeling in PH Patients, Study Shows

News, PAH News, PH News

Ventripoint Diagnostics‘ VMS Heart Analysis System, which produces a two-dimensional (2D) volumetric reconstruction model of the heart, accurately measures small changes in the heart’s right ventricle volume and can be used in ... Read more